Johnson & Johnson to close Synthes deal Thursday for $19.7 billion
Johnson & Johnson said it plans to complete the largest acquisition in company history, the takeover of medical device maker Synthes, Inc., on Thursday, with the final price of about $19.7 billion in cash and stock.
Johnson & Johnson to close Synthes deal Thursday for $19.7 billion
David Sell
Johnson & Johnson said Tuesday evening it plans to complete the largest acquisition in company history, the takeover of medical device maker Synthes, Inc., on Thursday, with the final price of about $19.7 billion in cash and stock.
The previously announced tentative price of $21.3 billion was subject to currency and stock prices at the time of closing.
J&J is based in New Brunswick, N.J., and has operations around the globe, including the Philadelphia region. Synthes has headquarters in Switzerland and in West Chester, Chester County.
The last regulatory hurdle was cleared Monday, when the U.S. Federal Trade Commission approved the deal, pending J&J's sale of wrist devices to Biomet. J&J previously said it would sell all of its DePuy trauma device to Biomet to satisfy regulators.
The press release is here.
- Adolor
- Almac
- AmerisourceBergen
- AstraZeneca
- Auxilium
- Bayer
- Celgene
- Cephalon
- Endo
- GlaxoSmithKline
- Johnson & Johnson
- Kensey Nash
- Lannett
- Merck
- Pfizer
- Roche
- Sanofi-aventis
- Shire
- Stryker
- Synthes
- Teva
- ViroPharma
- West
- Centers for Disease Control and Prevention
- Centers for Medicare and Medicaid
- Clinical Trials
- Food and Drug Administration
- Office of Inspector General, Health and Human Services
- OIG Most-wanted list of fugitives
- Securities and Exchange Commission/Edgar filings
- U.S. Attorney's Office/Eastern Pennsylvania, health-care fraud
- U.S. Department of Health and Human Services
- BIO
- Jersey Association of Medical Equipment Services
- Pennsylvania Association of Medical Suppliers
- Pharmaceutical Research and Manufacturers of America
- Science Center
- American Health Lawyers Association
- Drug and Device Law
- Orange Book blog
- Taxpayers Against Fraud
- Bio Century
- Bio Space
- Cafe Pharma
- Financial Times
- In The Pipeline
- Monday Morning
- New York Times/Prescriptions
- Pharma Live
- Pharma Marketing
- Pharmalot
- The Placebo Effect
- Wall Street Journal/Health blog
